WO2001059110A3 - 34p3d7: proteine specifique aux tissus hautement exprimes dans le cancer de la prostate - Google Patents

34p3d7: proteine specifique aux tissus hautement exprimes dans le cancer de la prostate Download PDF

Info

Publication number
WO2001059110A3
WO2001059110A3 PCT/US2001/004094 US0104094W WO0159110A3 WO 2001059110 A3 WO2001059110 A3 WO 2001059110A3 US 0104094 W US0104094 W US 0104094W WO 0159110 A3 WO0159110 A3 WO 0159110A3
Authority
WO
WIPO (PCT)
Prior art keywords
tissue specific
prostate cancer
specific protein
highly expressed
protein highly
Prior art date
Application number
PCT/US2001/004094
Other languages
English (en)
Other versions
WO2001059110A2 (fr
Inventor
Mary Faris
Daniel E H Afar
Pia M Challita-Eid
Rene S Hubert
Elana Levin
Steve Chappell Mitchell
Aya Jakobovits
Original Assignee
Urogenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urogenesys Inc filed Critical Urogenesys Inc
Priority to AU2001236782A priority Critical patent/AU2001236782A1/en
Publication of WO2001059110A2 publication Critical patent/WO2001059110A2/fr
Publication of WO2001059110A3 publication Critical patent/WO2001059110A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un nouveau gène (appelé 34P3D7) et sa protéine codée. Tandis que le gène 34P3D7 présente une expression spécifique aux tissus dans des tissus adultes normaux, il est exprimé de façon aberrante dans des cancers multiples notamment dans les cancers de la prostate, de la vessie, des reins, du cerveau, des os, du col, de l'utérus, des ovaires, du sein, du pancréas, de l'estomac, du colon, du rectum, des leucocytes, du foie et des poumons. Par conséquent, le gène 34P3D7 constitue une cible diagnostique et/ou thérapeutique pour les cancers, et le gène 34P3D7 ou un fragment de celui-ci, ou sa protéine codée ou un fragment de celle-ci peut être utilisé pour faire apparaître une réponse immune.
PCT/US2001/004094 2000-02-08 2001-02-08 34p3d7: proteine specifique aux tissus hautement exprimes dans le cancer de la prostate WO2001059110A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001236782A AU2001236782A1 (en) 2000-02-08 2001-02-08 34p3d7: a tissue specific protein highly expressed in prostate cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18102000P 2000-02-08 2000-02-08
US60/181,020 2000-02-08

Publications (2)

Publication Number Publication Date
WO2001059110A2 WO2001059110A2 (fr) 2001-08-16
WO2001059110A3 true WO2001059110A3 (fr) 2002-02-21

Family

ID=22662558

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/004094 WO2001059110A2 (fr) 2000-02-08 2001-02-08 34p3d7: proteine specifique aux tissus hautement exprimes dans le cancer de la prostate

Country Status (3)

Country Link
US (1) US20020150972A1 (fr)
AU (1) AU2001236782A1 (fr)
WO (1) WO2001059110A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055735A2 (fr) * 2000-11-27 2002-07-18 Diadexus Inc Compositions et methodes en rapport avec des genes et des proteines specifiques de la prostate
CA2480811A1 (fr) * 2002-04-01 2003-10-16 Agensys, Inc. Acide nucleique et proteine correspondante 213p1f11 que l'on utilise dans le traitement et la detection du cancer
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd Peptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004149A2 (fr) * 1998-07-14 2000-01-27 Corixa Corporation Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2000073801A2 (fr) * 1999-05-28 2000-12-07 Ludwig Institute For Cancer Research Antigenes associes au cancer du sein, de la prostate et de l'estomac et leur utilisation
EP1074617A2 (fr) * 1999-07-29 2001-02-07 Helix Research Institute Amorces pour la synthèse de cADN de pleine longueur et leur utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004149A2 (fr) * 1998-07-14 2000-01-27 Corixa Corporation Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2000073801A2 (fr) * 1999-05-28 2000-12-07 Ludwig Institute For Cancer Research Antigenes associes au cancer du sein, de la prostate et de l'estomac et leur utilisation
EP1074617A2 (fr) * 1999-07-29 2001-02-07 Helix Research Institute Amorces pour la synthèse de cADN de pleine longueur et leur utilisation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 17 November 1999 (1999-11-17), HCGP: "CM2-CT0128-160899-003-g12 CT0128 Homo sapiens cDNA, mRNA sequence.", XP002178332 *
DATABASE EMBL 26 April 1999 (1999-04-26), NCI-CGAP: "ty19a11.x1 NCI_CGAP_Ut3 Homo sapiens cDNA clone IMAGE:2279516 3', mRNA sequence.", XP002178331 *
INAGAKI NOBUYA ET AL: "Cloning of a Mouse Rabphilin-3A Expressed in Hormone-Secreting Cells.", JOURNAL OF BIOCHEMISTRY (TOKYO), vol. 116, no. 2, 1994, pages 239 - 242, XP002178330, ISSN: 0021-924X *
REITER ET AL: "PROSTATE STEM CELL ANTIGEN: A CELL SURFACE MARKER OVEREXPRESSED IN PROSTATE CANCER", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, no. 95, 1 February 1998 (1998-02-01), pages 1735 - 1740, XP002078363, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2001059110A2 (fr) 2001-08-16
AU2001236782A1 (en) 2001-08-20
US20020150972A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
WO2002010382A3 (fr) Marqueurs trp8, trp9 et trp10 associes au cancer
WO2004113571A3 (fr) Genes specifiques de la prostate et leur utilisation comme cibles dans le traitement et le diagnostic du cancer de la prostate
IL147902A0 (en) C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
WO2005062972A3 (fr) Traitement du cancer au moyen de nouveaux anticorps monoclonaux anti-il 13
MXPA03001634A (es) Polipeptido tumoral cripto.
WO2005054295A8 (fr) Anticorps therapeutiques et diagnostiques anti-hsp 70
WO2001059110A3 (fr) 34p3d7: proteine specifique aux tissus hautement exprimes dans le cancer de la prostate
IL207012A (en) 28sgp medicinal product and 28sgp accent cancer treatment vaccine
WO2001059115A3 (fr) Le 83p5g4: proteine specifique de tissus fortement exprime dans le cancer de la prostate
WO2001062925A3 (fr) 103p2d6: proteine specifique de certains tissus, fortement exprimee dans divers cancers
EP0839908A3 (fr) ELF3, un membre de la famille ETS
WO2002014361A3 (fr) Acides nucleiques et proteines correspondantes appeles 83p2h3 et catrf2e11 utiles dans le traitement et la detection du cancer
WO2001079557A3 (fr) Proteine de fixation gtp pour le traitement et la detection du cancer
WO2001055391A3 (fr) 84p2a9: proteine specifique de la prostate et du testicule fortement exprimee dans le cancer de la prostate
WO2001090157A8 (fr) 98p7c3: proteine a homeodomaine fortement exprimee dans divers cancers
WO2001096391A3 (fr) 55p4h4: gene exprime dans divers cancers
WO2002043572A3 (fr) Erythropoietine et expression du recepteur de l"erythropoietine dans le cancer humain
WO2002002772A3 (fr) Marqueur tumoral associe a la matrice extracellulaire
WO2003020954A3 (fr) Acide nucleique et proteine correspondante appelee 205p1b5 utilises dans le traitement et la detection du cancer
WO2004078123A3 (fr) Antigenes precoces du cancer de la prostate (epca), sequences polynucleotidiques codant ces antigenes, et leur utilisation
AU2002365104A8 (en) Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof
WO2003042700A3 (fr) Polypeptide associe au cancer du sein
GB0121818D0 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
GB0118387D0 (en) Proteins,genes and their use for diagnosis and treatment of breast cancer
GB0120926D0 (en) Proteins,genes and their use for diagnosis and treatment of breast cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP